Time filter

Source Type

Nerviano, Italy

Locatelli G.,Nerviano Medical science S.r.l | Bosotti R.,Nerviano Medical science S.r.l | Ciomei M.,Nerviano Medical science S.r.l | Brasca M.G.,Nerviano Medical science S.r.l | And 12 more authors.
Molecular Cancer Therapeutics | Year: 2010

A transcriptional signature of the pan-cyclin-dependent kinase (Cdk) inhibitor PHA-793887 was evaluated as a potential pharmacodynamic and/or response biomarker in tumor and skin biopsies from patients treated in a phase I clinical study. We first analyzed the expression of a number of known E2F-dependent genes that were predicted to be modulated after Cdk2 and Cdk4 inhibition in xenograft tumor and skin samples of mice treated with the compound. This panel of 58 selected genes was then analyzed in biopsies from seven patients treated with PHA-793887 in a phase I dose escalation clinical trial in solid tumors. Quantitative real-time PCR or microarray analyses were done in paired skin and tumor biopsies obtained at baseline and at cycle 1. Analysis by quantitative real-time PCR of the signature in skin biopsies of patients treated at three different doses showed significant transcriptional downregulation with a dose-response correlation. These data show that PHA-793887 modulates genes involved in cell cycle regulation and proliferation in a clinical setting. The observed changes are consistent with its mechanism of action and correlate with target modulation in skin and with clinical benefit in tumors.

Lee C.A.,QPS DMPK Hepatic Biosciences | Kalvass J.C.,Drug Metabolism | Galetin A.,University of Manchester | Zamek-Gliszczynski M.J.,Glaxosmithkline
Clinical Pharmacology and Therapeutics | Year: 2014

The "P-glycoprotein" IC 50 working group reported an 18- to 796-fold interlaboratory range in digoxin transport IC 50 (inhibitor concentration achieving 50% of maximal inhibition), raising concerns about the predictability of clinical transporter-based drug-drug interactions (DDIs) from in vitro data. This Commentary describes complexities of digoxin transport, which involve both uptake and efflux processes. We caution against attributing digoxin transport IC 50 specifically to P-glycoprotein (P-gp) or extending this composite uptake/efflux IC 50 variability to individual transporters. Clinical digoxin interaction studies should be interpreted as evaluation of digoxin safety, not P-gp DDIs.

The Center for Environmental Health Sciences (CEHS) at MIT held its annual poster session on May 4 in the Walker Memorial Building. The session highlighted the work of the environmental health research communities of MIT and some peer institutions. Approximately 50 posters were presented from the science and engineering laboratories affiliated with CEHS. The CEHS has an overall mission to study the biological effects of exposure to environmental agents in order to understand and predict how such exposures affect human health. Moreover, by uncovering the chemical, biochemical, and genetic bases for environmental disease, sometimes researchers are able to leverage that understanding to delay or even prevent the development of disease in human populations. To that end, the center brings together 39 MIT faculty members from a total of nine MIT departments in both the School of Science and the School of Engineering, plus one Harvard University faculty member from the Harvard School of Public Health. This year’s CEHS cash prizes were awarded in two categories, graduate students and postdocs. For each category, the prize for first-place was $1,000; second-place was $500, and third-place was $200 plus CEHS memorabilia. The cash prizes were made possible by the Myriam Marcelle Znaty Research Fund, which was established over 30 years ago to support the research of young scientists at MIT. Graduate students, postdocs, and research staff presented the results of their research at MIT's Morss Hall. Anthony R. Soltis from Professor Ernest Fraenkel’s lab won first place in the graduate student category. Soltis presented his work on the “Multi-Omic Data Collection and Integrative Modeling of High-Fat Diet-Induced Obesity Reveals Features of Hepatic Insulin Resistance.” In second place was Joseph M. Azzarelli and Rong Zhu from Professor Timothy Swager’s lab, who presented their work on “Wireless Hazard Badges for Organophosphate Acetylcholinesterase Inhibitors.” Finally, in third place was Chen Gu, from Professor Peter Dedon’s lab, presenting his work on “Phosphorylation of Human TRM9L Modulates its Functions in Oxidative Stress Management and Tumor Growth Suppression.” In the postdoc category, first place went to Collin Edington and Xin Wang from professors Linda Griffith and Steven R. Tannenbaum labs (respectively), presenting on “Construction and Evaluation of the In Vitro Central Nervous System Models.” Second place went to Renan Escalante-Chong, from Professor Ernest Fraenkel's lab, who presented his work on “Integrative Approaches for Cell Signature Generation in ALS Patients at NeuroLINCS.” And Nikolaos Tsamandouras, from Professor Linda Griffith’s lab, took third place after presenting his work on “Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused 3-D human Liver Bioreactor Along with Modeling and Simulation Techniques.”

Pero J.E.,PO Box 4 | Pero J.E.,Glaxosmithkline | Rossi M.A.,PO Box 4 | Kelly M.J.,PO Box 4 | And 13 more authors.
ACS Medicinal Chemistry Letters | Year: 2016

Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibited strong in vitro activity and attractive pharmacokinetic (PK) properties. Hypothesis-driven target design identified compound 21 as a potent, highly selective, orally bioavailable mGluR2 PAM, which addressed a CYP time-dependent inhibition (TDI) liability of 18, while maintaining excellent drug-like properties with robust in vivo activity in a clinically validated model of antipsychotic potential. © 2016 American Chemical Society.

Zheng J.,Drug Metabolism | Pflanz S.,Biology | Frey C.R.,Biology | Hesselgesser J.,Clinical Virology and Medicinal Chemistry | And 2 more authors.
Journal of Pharmacology and Experimental Therapeutics | Year: 2014

GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8- dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-molecule agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects associated with current systemic interferon-a (IFN-a) therapies. We characterized the pharmacodynamic response of GS-9620 in CD-1 mice and cynomolgus monkeys following intravenous or oral administration and showed that GS-9620 induces the production of select chemokines and cytokines, including IFN-a and interferon-stimulated genes (ISGs). It is noteworthy that we also demonstrated that, in animals and healthy human volunteers, oral administration of GS-9620 can induce a type I interferon-dependent antiviral innate immune response, as measured by whole-blood mRNA of the ISGs 2959-oligoadenylate synthetase 1 (OAS1) and myxovirus resistance 1 (MX1), without the induction of detectable systemic IFN-a, i.e., a presystemic response. Additionally, presystemic induction of hepatic OAS1 and MX1 mRNA was observed in CD-1 mice in the absence of detectable systemic IFN-a. We propose that the mechanism of this presystemic response is likely its high intestinal absorption,which facilitates localized activation of TLR7, probably in plasmacytoid dendritic cells at the level of gut-associated lymphoid tissue and/or the liver. This localized response is further supported by data that indicate onlyminimal contributions of systemic immune stimulation to the overall pharmacodynamic response to orally administered GS-9620. These data demonstrate that GS-9620 can induce an antiviral innate immune response without inducing a systemic IFN-a response and thus suggest the therapeutic potential of this approach in the treatment of chronic HBV infection. Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics.

Discover hidden collaborations